PPD Competitors

PPD (NASDAQ:PPD) and IQVIA (NYSE:IQV) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, analyst recommendations, dividends, earnings and institutional ownership.

Profitability

This table compares PPD and IQVIA's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for PPD and IQVIA, as provided by MarketBeat.com.

PPD presently has a consensus target price of $43.3636, indicating a potential downside of 6.02%. IQVIA has a consensus target price of $243.8333, indicating a potential upside of 5.84%. Given IQVIA's stronger consensus rating and higher possible upside, analysts clearly believe IQVIA is more favorable than PPD.

Insider and Institutional Ownership

68.8% of PPD shares are owned by institutional investors. Comparatively, 87.2% of IQVIA shares are owned by institutional investors. 6.0% of IQVIA shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares PPD and IQVIA's top-line revenue, earnings per share and valuation.

IQVIA has higher revenue and earnings than PPD. IQVIA is trading at a lower price-to-earnings ratio than PPD, indicating that it is currently the more affordable of the two stocks.

Summary

IQVIA beats PPD on 11 of the 13 factors compared between the two stocks.

Incyte (NASDAQ:INCY) and PPD (NASDAQ:PPD) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent recommendations for Incyte and PPD, as provided by MarketBeat.

Incyte presently has a consensus price target of $99.50, indicating a potential upside of 20.88%. PPD has a consensus price target of $43.3636, indicating a potential downside of 6.02%. Given Incyte's stronger consensus rating and higher probable upside, equities analysts plainly believe Incyte is more favorable than PPD.

Profitability

This table compares Incyte and PPD's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Incyte and PPD's top-line revenue, earnings per share and valuation.

Incyte has higher earnings, but lower revenue than PPD. Incyte is trading at a lower price-to-earnings ratio than PPD, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

91.4% of Incyte shares are held by institutional investors. Comparatively, 68.8% of PPD shares are held by institutional investors. 16.1% of Incyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Incyte beats PPD on 8 of the 13 factors compared between the two stocks.

PPD (NASDAQ:PPD) and Exact Sciences (NASDAQ:EXAS) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Profitability

This table compares PPD and Exact Sciences' net margins, return on equity and return on assets.

Insider & Institutional Ownership

68.8% of PPD shares are held by institutional investors. Comparatively, 90.4% of Exact Sciences shares are held by institutional investors. 1.8% of Exact Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and recommmendations for PPD and Exact Sciences, as provided by MarketBeat.

PPD presently has a consensus price target of $43.3636, indicating a potential downside of 6.02%. Exact Sciences has a consensus price target of $154.20, indicating a potential upside of 63.33%. Given Exact Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Exact Sciences is more favorable than PPD.

Valuation & Earnings

This table compares PPD and Exact Sciences' revenue, earnings per share (EPS) and valuation.

PPD has higher revenue and earnings than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than PPD, indicating that it is currently the more affordable of the two stocks.

Summary

PPD beats Exact Sciences on 7 of the 13 factors compared between the two stocks.

PPD (NASDAQ:PPD) and Charles River Laboratories International (NYSE:CRL) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

Profitability

This table compares PPD and Charles River Laboratories International's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and price targets for PPD and Charles River Laboratories International, as reported by MarketBeat.com.

PPD currently has a consensus target price of $43.3636, indicating a potential downside of 6.02%. Charles River Laboratories International has a consensus target price of $286.4167, indicating a potential downside of 10.45%. Given PPD's higher possible upside, research analysts plainly believe PPD is more favorable than Charles River Laboratories International.

Insider and Institutional Ownership

68.8% of PPD shares are held by institutional investors. Comparatively, 92.3% of Charles River Laboratories International shares are held by institutional investors. 1.9% of Charles River Laboratories International shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares PPD and Charles River Laboratories International's revenue, earnings per share (EPS) and valuation.

Charles River Laboratories International has lower revenue, but higher earnings than PPD. PPD is trading at a lower price-to-earnings ratio than Charles River Laboratories International, indicating that it is currently the more affordable of the two stocks.

Summary

Charles River Laboratories International beats PPD on 10 of the 13 factors compared between the two stocks.

PPD (NASDAQ:PPD) and ICON Public (NASDAQ:ICLR) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Valuation & Earnings

This table compares PPD and ICON Public's revenue, earnings per share (EPS) and valuation.

ICON Public has lower revenue, but higher earnings than PPD. ICON Public is trading at a lower price-to-earnings ratio than PPD, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

68.8% of PPD shares are owned by institutional investors. Comparatively, 81.7% of ICON Public shares are owned by institutional investors. 44.0% of ICON Public shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations for PPD and ICON Public, as reported by MarketBeat.

PPD presently has a consensus price target of $43.3636, suggesting a potential downside of 6.02%. ICON Public has a consensus price target of $236.00, suggesting a potential upside of 5.25%. Given ICON Public's stronger consensus rating and higher probable upside, analysts plainly believe ICON Public is more favorable than PPD.

Profitability

This table compares PPD and ICON Public's net margins, return on equity and return on assets.

Summary

ICON Public beats PPD on 11 of the 13 factors compared between the two stocks.

PRA Health Sciences (NASDAQ:PRAH) and PPD (NASDAQ:PPD) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and profitability.

Institutional and Insider Ownership

96.1% of PRA Health Sciences shares are owned by institutional investors. Comparatively, 68.8% of PPD shares are owned by institutional investors. 1.3% of PRA Health Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares PRA Health Sciences and PPD's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings for PRA Health Sciences and PPD, as reported by MarketBeat.com.

PRA Health Sciences presently has a consensus price target of $145.00, suggesting a potential downside of 15.02%. PPD has a consensus price target of $43.3636, suggesting a potential downside of 6.02%. Given PPD's stronger consensus rating and higher probable upside, analysts plainly believe PPD is more favorable than PRA Health Sciences.

Earnings & Valuation

This table compares PRA Health Sciences and PPD's revenue, earnings per share (EPS) and valuation.

PRA Health Sciences has higher earnings, but lower revenue than PPD. PRA Health Sciences is trading at a lower price-to-earnings ratio than PPD, indicating that it is currently the more affordable of the two stocks.

Summary

PRA Health Sciences beats PPD on 7 of the 13 factors compared between the two stocks.